Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection

被引:109
作者
Brys, L
Beschin, A
Raes, G
Ghassabeh, GH
Noël, W
Brandt, J
Brombacher, F
De Baetselier, P
机构
[1] Free Univ Brussels VIB, Dept Cellular & Mol Interact, B-1050 Brussels, Belgium
[2] Inst Trop Geneeskunde, Diergeneeskunde, Antwerp, Belgium
[3] Univ Cape Town, Fac Hlth Sci, ZA-7925 Cape Town, South Africa
基金
英国惠康基金;
关键词
D O I
10.4049/jimmunol.174.10.6095
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Understanding the role of CD11b(+)GR-1(+) myeloid suppressor cells in the immune suppression and immunoregulation associated with a variety of diseases may provide therapeutic opportunities. In this article, we show, in a model of helminth infection, that CD11b(+)GR-1(+) myeloid suppressor cells but not CD11b(+)F4/80(high) mature macrophages expanded in the peritoneal cavity of BALB/c mice implanted with Taenia crassiceps. Peritoneal cell populations from early stage-infected animals impaired T cell proliferation by secreting NO. Yet, they lost their ability to secrete NO in the late stage of infection. Concomitantly, their capacity to exert arginase activity and to express mRNAs coding for FIZZ1 (found in inflammatory zone 1), Ym, and macrophage galactose-type C-type lectin increased. Furthermore, cells from early stage-infected mice triggered T cells to secrete IFN-gamma and IL-4, whereas in the late stage of infection, they only induced IL-4 production. These data suggest that CD11b(+)GR-1(+) myeloid suppressor cells displaying an alternative activation phenotype emerged gradually as T. crassiceps infection progressed. Corroborating the alternative activation status in the late stage of infection, the suppressive activity relied on arginase activity, which facilitated the production of reactive oxygen species including H2O2 and superoxide. We also document that the suppressive activity of alternative myeloid suppressor cells depended on 12/15-lipoxygenase activation generating lipid mediators, which triggered peroxisome proliferator-activated receptor-gamma. IL-4 and IL-13 signaling contributed to the expansion of myeloid suppressor cells in the peritoneal cavity of T. crassiceps-infected animals and to their antiproliferative activity by allowing arginase and 12/15-lipoxygenase gene expression.
引用
收藏
页码:6095 / 6104
页数:10
相关论文
共 76 条
  • [21] INTERLEUKIN-13 - NOVEL ROLE IN DIRECT REGULATION OF PROLIFERATION AND DIFFERENTIATION OF PRIMITIVE HEMATOPOIETIC PROGENITOR CELLS
    JACOBSEN, SEW
    OKKENHAUG, C
    VEIBY, OP
    CAPUT, D
    FERRARA, P
    MINTY, A
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) : 75 - 82
  • [22] Clinical, virological and histopathological features:: long-term follow-up in patients with chronic hepatitis C co-infected with S-mansoni
    Kamal, S
    Madwar, M
    Bianchi, L
    Tawil, AEL
    Fawzy, R
    Peters, T
    Rasenack, JWF
    [J]. LIVER, 2000, 20 (04): : 281 - 289
  • [23] KULLBERG MC, 1992, J IMMUNOL, V148, P3264
  • [24] Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species
    Kusmartsev, S
    Nefedova, Y
    Yoder, D
    Gabrilovich, DI
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (02) : 989 - 999
  • [25] IL-4 plays a crucial role in regulating oxidative damage in the liver during schistosomiasis
    La Flamme, AC
    Patton, EA
    Bauman, B
    Pearce, EJ
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (03) : 1903 - 1911
  • [26] Role of immature myeloid Gr-1+ cells in the development of antitumor immunity
    Li, QS
    Pan, PY
    Gu, PD
    Xu, DP
    Chen, SH
    [J]. CANCER RESEARCH, 2004, 64 (03) : 1130 - 1139
  • [27] Nitric oxide-independent CTL suppression during tumor progression: Association with arginase-producing (M2) myeloid cells
    Liu, YQ
    Van Ginderachter, JA
    Brys, L
    De Baetselier, P
    Raes, G
    Geldhof, AB
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (10) : 5064 - 5074
  • [28] Loke P, 2000, EUR J IMMUNOL, V30, P2669, DOI 10.1002/1521-4141(200009)30:9&lt
  • [29] 2669::AID-IMMU2669&gt
  • [30] 3.0.CO